PT-141: Side Effects

Safety Notice#

Safety Overview#

PT-141 (bremelanotide) has one of the most well-characterized safety profiles of any peptide covered on this site, owing to its FDA-approved status and the comprehensive clinical development program that preceded approval. The safety database includes data from two Phase 3 randomized controlled trials (RECONNECT), a 52-week open-label extension, and ongoing post-marketing surveillance.

The overall safety profile is characterized by predominantly mild to moderate adverse events, with nausea being the most significant tolerability concern. The majority of adverse events (31% mild, 40% moderate) were transient and manageable. Serious adverse events were rare in the clinical development program.

Clinical Trial Adverse Events#

Phase 3 RECONNECT Trial Data#

The following adverse events were reported in the pivotal Phase 3 trials at rates of 2% or higher in the bremelanotide group:

Nausea: The Primary Tolerability Concern#

Nausea is the dominant adverse event with PT-141, affecting approximately 40% of patients in clinical trials compared to only 1.3% on placebo. Key characteristics of PT-141-induced nausea include:

• Onset: Typically within 1-2 hours of subcutaneous injection
• Severity: Predominantly mild (31%) to moderate (40%) intensity
• Duration: Usually resolves within a few hours
• Habituation: Tends to decrease in frequency and severity with continued use
• Discontinuation: Nausea was the most common reason for study discontinuation (8% of bremelanotide-treated patients, 2% with headache, 1% each for vomiting and flushing)

The nausea is likely mediated by melanocortin receptor activation in the area postrema (the chemoreceptor trigger zone), a brain region involved in nausea and vomiting that lies outside the blood-brain barrier and is accessible to circulating peptides.

Flushing#

Flushing affects approximately 20% of patients and is characterized by warmth and redness, typically in the face and upper body. This effect is related to melanocortin receptor-mediated vasodilation and is generally mild and self-limiting. Flushing typically occurs within the first hour of dosing and resolves within a few hours.

Blood Pressure Effects#

PT-141 produces transient increases in blood pressure after each dose. The clinical significance of these changes has been carefully evaluated:

• Mean change: +1.9 mmHg systolic, +1.7 mmHg diastolic (daytime ambulatory blood pressure monitoring)
• Heart rate: Small decrease observed
• Duration: Changes resolve within 12 hours of dosing
• Outliers: Approximately 1% of bremelanotide-treated patients had individual readings of 180/110 mmHg or higher
• Clinical significance: The FDA label recommends caution in patients at risk for cardiovascular disease and states that blood pressure should be well controlled before initiating treatment

The blood pressure effects are likely mediated through central melanocortin receptors involved in cardiovascular regulation and possibly through peripheral MC1R activation.

Focal Hyperpigmentation#

A unique adverse effect of PT-141, related to its residual MC1R activity, is focal hyperpigmentation. This manifests as darkening of skin in specific areas, most commonly the face, gingiva (gums), and breasts. The hyperpigmentation may develop gradually with repeated use and can be persistent after discontinuation.

The mechanism is stimulation of melanogenesis through MC1R activation in melanocytes. While reduced compared to Melanotan-2, PT-141 retains sufficient MC1R activity to cause pigmentation changes in susceptible individuals.

Long-Term Safety#

52-Week Extension Data#

The 52-week open-label extension of the RECONNECT trials provided the longest safety follow-up available for PT-141:

• No new safety signals emerged with extended use
• The adverse event profile remained consistent with the 24-week Phase 3 data
• Nausea continued to be the most common adverse event but was generally manageable
• No cumulative toxicity or organ damage was identified
• The blood pressure effects did not worsen with repeated dosing

Post-Marketing Safety#

Since FDA approval in June 2019, post-marketing surveillance has continued to monitor PT-141 safety. The post-marketing experience has been consistent with the clinical trial safety profile, with nausea, flushing, and headache as the most commonly reported adverse events.

Contraindications#

FDA-Labeled Contraindications#

The Vyleesi prescribing information includes the following contraindications and warnings:

• Uncontrolled hypertension: Due to transient blood pressure increases
• Cardiovascular disease: Use with caution in patients at risk for cardiovascular events
• Naltrexone: Bremelanotide may reduce the efficacy of naltrexone-containing products (this interaction is included in the label and concurrent use is not recommended)

Populations Not Studied#

The following populations were not included in Phase 3 clinical trials:

• Postmenopausal women
• Men (for HSDD indication)
• Patients under 18 or over 55 years of age
• Patients with significant cardiovascular disease
• Patients with uncontrolled hypertension
• Pregnant or breastfeeding women

Drug Interactions#

Naltrexone Interaction#

The most clinically significant drug interaction is with naltrexone. Bremelanotide may reduce the efficacy of naltrexone-containing products. This is relevant for patients taking naltrexone for alcohol use disorder or opioid use disorder. The mechanism is thought to involve melanocortin-opioid pathway cross-talk. The FDA label states that concurrent use is not recommended.

Blood Pressure Medications#

Bremelanotide's transient blood pressure effects could interact with antihypertensive medications. The clinical significance is likely minimal given the small magnitude and transient nature of the blood pressure changes, but monitoring is recommended in patients on blood pressure-lowering therapy.

Oral Medications#

Bremelanotide-induced nausea and potential vomiting could affect the absorption of concomitantly administered oral medications. Patients taking time-sensitive oral medications should be advised of this possibility.

Special Populations#

Hepatic Impairment#

Limited data in hepatic impairment. PT-141 is cleared primarily through peptide hydrolysis and renal excretion, suggesting hepatic impairment may have limited impact on pharmacokinetics. However, no formal hepatic impairment study has been published.

Renal Impairment#

Approximately 65% of the dose is excreted renally. Patients with significant renal impairment may have altered exposure, but no dose adjustment recommendations exist because this population was not systematically studied.

Pregnancy and Lactation#

PT-141 has not been studied in pregnant or lactating women. It is not indicated for use during pregnancy or breastfeeding. The effects of melanocortin receptor activation on fetal development and breast milk production are unknown.

Monitoring Recommendations#

Before Initiating Treatment#

• Blood pressure measurement (ensure well-controlled)
• Cardiovascular risk assessment
• Skin examination (baseline for hyperpigmentation monitoring)
• Review concomitant medications (particularly naltrexone)

During Treatment#

• Periodic blood pressure monitoring
• Assessment of nausea and tolerability
• Skin examination for hyperpigmentation changes
• Efficacy assessment

Evidence Gaps#

• Safety in postmenopausal women not established
• Long-term safety beyond 52 weeks of regular use
• Safety in patients with cardiovascular disease not systematically studied
• Pregnancy and lactation safety data absent
• Effect on fertility unknown
• Carcinogenicity related to MC1R activation and hyperpigmentation not fully excluded
• Drug interactions beyond naltrexone not systematically evaluated

Related Reading#

• PT-141 overview and research guide
• PT-141 dosing protocols
• PT-141 risks and legal status